

July 27, 2023

BSE LIMITED	Code: 532 321	NATIONAL STOCK EXC LIMITED	CHANGE OF INDIA Code: <i>Zyduslife</i>
P J Towers, Dalal Street, Fort Mumbai-400001	,	Exchange Plaza, Band Bandra (E), Mumbai-400	•

Re.: <u>Intimation under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")</u>

Dear Sir / Madam,

We would like to inform that the Company, as a joint venture partner, has signed an agreement to amend certain clauses of the joint venture agreement ("JVA") with Bayer (South East Asia) PTE Limited, one of the companies of the Bayer group.

Additional disclosures, with regard to amendment of the JVA, as required under regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are given in **Annexure-1**.

We request you to kindly take this on record.

Thanking you,

Yours Sincerely For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above



Annexure-1

Sr. No.	Particulars	Responses			
1.	name(s) of parties with whom the agreement is entered	Zydus Lifesciences Limited ("the Company") or "JV Partner 1")			
		Bayer (South East Asia) PTE Limited ("Bayer" or "JV Partner 2")			
		3. Bayer Zydus Pharma Private Limited ("JV Company")			
		JV Partner 1 and JV Partner 2 are collectively referred to as "JV Partners".			
2.	purpose of entering into the agreement	JV Partners entered into an agreement ("JVA") dated January 28, 2011 and pursuant to which the JV Partners formed a joint venture company i.e. JV Company.			
		The purpose of entering into the JVA is for carrying on business of marketing of pharmaceutical products.			
3.	shareholding, if any, in the entity with whom the agreement is executed	As on date, the shareholding structure of the JV Company is as under:			
		Sr. Name of the No. of % of shares No. Company Equity shares			
		1. Zydus Lifesciences 1,24,99,999 24.9999 Limited			
		2. Bayer South East 3,75,00,001 75.0001 Asia PTE Limited			
		Total 5,00,00,000 100.00			
		Sr. Name of the No. of % of shares Preference shares			
		1. Zydus Lifesciences 60,00,000 25.00 Limited			



	Siedeed to Elife		D	4 00 00 000	75.00
		2.	Bayer Pharmaceuticals Private Limited	1,80,00,000	75.00
		Total		2,40,00,000	100.00
		The Co	ompany is not hor r 2.	olding any s	hares of JV
4.	significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	nomin There	tner 1 and JV P ate 3 and 5 direct are detailed tions on transfer o	ors respectiv	vely.
5.	whether the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship		of the parties are oter group / gr er.		•
6.	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"		The transaction is not within related party transaction.		
7.	in case of issuance of shares to the parties, details of issue price, class of shares issued	On incorporation of the JV Company, the equity shares were issued to the JV Partners at face value of Rs. 10/- each.			
8.			JV Partners are not entitled to nominate any Director on the Board of the Company. There is no potential conflict of interest arising out of the JVA.		



Sr.	Particulars	Responses		
No.	1 41 41 41 41 41			
9.	in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s)	There are certain amendments in the JVA and the details thereof are provided hereinbelow.		
a.	name of parties to the agreement	JV Partners and the JV Company.		
b.	nature of the agreement	An agreement to amend certain clauses of the JVA.		
C.	date of execution of the agreement	July 27, 2023		
d.	details of amendment and impact thereof or reasons of termination and impact thereof	An agreement to amend certain clauses of the JVA to enable participation in tenders of some government institutions / public sector undertakings for some products through an affiliate entity of a JV Partner.		

For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI COMPANY SECRETARY